Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients.
The last earnings update was 37 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Magenta Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Magenta Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Magenta Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Magenta Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Magenta Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Magenta Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Magenta Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Magenta Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Magenta Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Magenta Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Jason Gardner, Ph.D., is Cofounder of Magenta Therapeutics, Inc. and has been its Chief Executive Officer and President since February 2016. Mr. Gardner joined Atlas Venture in November 2015 as an Atlas Advisor to create Magenta and has 21 years combined experience in stem cell science and industry leadership roles. He worked at GSK for 11 years, most recently as Vice President and Head of the R&D Satellite in Boston. He created and led the Regenerative Medicine Unit, established partnerships with The Harvard Stem Cell Institute and The Telethon Institute for Gene Therapy from which the first stem cell medicine (Strimvelis™) was approved. He was formerly a scientist at Progenics Pharmaceuticals and Chiron. Mr. Gardner was the Head of the Center of Excellence for External Drug Discovery (CEEDD) and was as a member of the clinical project team that led the late stage development and NDA approval for Tykerb™ for breast cancer. He has been a Director of Magenta Therapeutics, Inc. since February 2016. He has worked on multiple successful modalities across a range of therapeutic areas from target to launch. Mr. Gardner completed a postdoctoral fellowship in hematopoietic stem cells at Harvard Medical School. He was educated in the UK and holds a D.Phil. from Oxford University and M.A. and B.A. degrees from Cambridge University.
Insufficient data for Jason to compare compensation growth.
Jason's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Magenta Therapeutics management team is less than 2 years, this suggests a new team.
Chief Scientific Officer
Chief Operating & Financial Officer
Vice President of Investor Relations & Communications
Chief Legal Officer
Head of Culture & People
Chief Business Officer
Chief Medical Officer
Head of Clinical Development Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Magenta Therapeutics board of directors is less than 3 years, this suggests a new board.
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.